Printer Friendly

GeneProt Expands its Proteomic Capabilities Through a New Scientific Agreement.

GENEVA, Switzerland, February 5 /PRNewswire/ -- - GeneProt amends its collaboration with Novartis Pharma

GeneProt Inc. today announced that it has amended its scientific collaboration with Novartis Pharma AG. The new collaboration will maximize the value from the synergy of GeneProt's industrial-scale approach to proteomics and Novartis' high-throughput biological validation platforms.

In October 2000, GeneProt and Novartis entered into a four-year collaboration to perform large scale proteomic studies for different therapeutic areas. Under the new collaboration agreement, GeneProt will continue to use its large scale proteomics platform and will accelerate the delivery of proteins to Novartis for further biological evaluation.

GeneProt will also take advantage of the new platforms it has developed to perform innovative proteomics such as accelerated studies on non-pooled samples, or pharmacoproteomics. Financial details were not disclosed.

"It is necessary to follow industrial-scale discovery with industrial-scale biological evaluation and also to stay at the forefront of a rapidly evolving industrial environment. We are pleased to offer these cutting edge proteomics services to Novartis. We look forward to continued collaboration with Novartis to leverage our combined expertise in an effort to accelerate the pace of pharmaceutical innovation," said Bertrand Damour, GeneProt's President and CEO.

About GeneProt(R)

GeneProt Inc. is an industrial-scale proteomic company focused on separating, identifying, characterising, selecting and synthesising human proteins on behalf of life sciences companies and for its own account for use in the discovery and development of new therapeutic proteins, protein drug targets and protein biomarkers. GeneProt analyses polypeptides and smaller proteins using its MicroProt(R) process at its industrial-scale proteomics facility in Geneva. One of the world's most powerful computers is used to analyse the complex information coming out from such studies. GeneProt's partners include leading pharmaceutical and technology companies and academic and scientific institutions such as Novartis, Serono, Hewlett Packard, Bruker Daltonics, Waters Corporation and the Swiss Institute of Bioinformatics. For more information please consult http://www.geneprot.com

Contact: Mr Bertrand Damour, phone: +41(0)22-719-39-00, Bertrand.Damour@Geneprot.com
COPYRIGHT 2004 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:4EXSI
Date:Feb 5, 2004
Words:329
Previous Article:Valentines Survey : Money can't buy you love, can it?
Next Article:Pot O' Gold Productions Records 160% Increase in Cinema Advertising Sales.
Topics:


Related Articles
GeneProt Board of Directors names Robert Parkinson as Chairman.
GENEPROT BOARD OF DIRECTORS NAMES ROBERT PARKINSON AS CHAIRMAN.
GENEPROT DELIVERS SIX SYNTHETIC PROTEINS TO NORVARTIS.
GeneProt licences Oxford's automated proteomics patents.
GeneProt, Duke University and Novartis Collaborate for Industrial-Scale Proteomic Study of Coronary Heart Disease.
GeneProt: Visit of the President of Romania, Mr. Ion Iliescu.
GeneProt: Visit of the President of Romania, Mr. Ion Iliescu; A Photo is Available from: info@lightmotif.ch.
[0] GeneProt Expands its Proteomic Capabilities Through a New Scientific Agreement.
GeneProt and Lundbeck Collaborate in CNS Proteomics.
GeneProt and Lundbeck Collaborate in CNS Proteomics.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters